Holen Sie sich die Stockscreener-App
44.36
1.32%
0.58
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CVS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$43.78
Offen:
$43.72
24-Stunden-Volumen:
19.00M
Relative Volume:
1.53
Marktkapitalisierung:
$55.82B
Einnahmen:
$368.91B
Nettoeinkommen (Verlust:
$5.02B
KGV:
6.6908
EPS:
6.63
Netto-Cashflow:
$1.69B
1W Leistung:
-10.15%
1M Leistung:
-21.94%
6M Leistung:
-27.28%
1J Leistung:
-42.57%
1-Tages-Spanne:
$43.68
$44.77
1-Wochen-Bereich:
$43.60
$49.12
52-Wochen-Spanne:
$43.60
$83.25
Cvs Health Corp Stock (CVS) Company Profile
Firmenname
Cvs Health Corp
Sektor
Branche
Telefon
(401) 765-1500
Adresse
ONE CVS DR., WOONSOCKET
Vergleichen Sie CVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
44.36 | 55.82B | 368.91B | 5.02B | 1.69B | 3.94 |
|
UNH
Unitedhealth Group Inc
|
500.13 | 460.26B | 389.07B | 14.32B | 13.10B | 15.35 |
|
ELV
Elevance Health Inc
|
365.96 | 84.87B | 174.02B | 6.42B | 871.00M | 27.43 |
|
CI
Cigna Group
|
276.92 | 77.03B | 229.75B | 3.04B | 5.18B | 10.60 |
|
CNC
Centene Corp
|
59.58 | 30.08B | 161.73B | 3.07B | 245.00M | 5.76 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-03 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-05-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-05-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-22 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Eingeleitet | Goldman | Buy |
| 2021-12-01 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-01-08 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-17 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-06-05 | Hochstufung | Standpoint Research | Hold → Buy |
| 2019-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-04-15 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-13 | Eingeleitet | Bernstein | Outperform |
| 2019-02-20 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-18 | Eingeleitet | Barclays | Overweight |
| 2018-11-29 | Fortgesetzt | Goldman | Neutral |
| 2018-11-28 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-26 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2018-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-02-13 | Bestätigt | Citigroup | Neutral |
Alle ansehen
Cvs Health Corp Aktie (CVS) Neueste Nachrichten
Principal Financial Group Inc. Acquires 66,244 Shares of CVS Health Co. (NYSE:CVS) - MarketBeat
Jim Cramer on CVS Health Corporation (CVS): ‘CVS Is A Real Company’ - Insider Monkey
CVS Health Corp. to lay off another 164 employees connected to Aetna Hartford site - Hartford Courant
CVS Accused of Illegal Opioid Dispensing in Federal Suit - MSN
Why CVS Health (CVS) Outpaced the Stock Market Today - Yahoo Canada Finance
Varo Bank Introduces Zero Fee Cash Deposits at Participating CVS Locations - Quantisnow
Why CVS Health (CVS) Is the Best Dividend Leader to Buy According to Wall Street Analysts? - Insider Monkey
CVS class action alleges retailer allows third parties to access mobile app communications - Top Class Actions
FY2024 EPS Estimates for CVS Health Cut by Leerink Partnrs - MarketBeat
CVS Health Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Civil Lawsuit Accuses CVS Of Facilitating Unlawful Sale Of Opioid Prescriptions For Profit - RTTNews
CVS Health (NYSE:CVS) Shares Gap DownShould You Sell? - MarketBeat
Peering Into CVS Health's Recent Short Interest - Benzinga
CVS stock touches 52-week low at $43.93 amid market challenges - Investing.com Canada
Feds accuse CVS of filling ‘thousands’ of illicit opioid prescriptions - STAT
Aetna adds Spanish language capabilities for health app to better serve diverse populations - CVS Health
Aetna Adds Spanish Language Capabilities for Health App to Better Serve Diverse Populations - PR Newswire
CVS contributing to US opioid crisis, Justice Department alleges - Proactive Investors UK
DOJ files complaint against CVS for filling ’unlawful' prescriptions of opioids and seeking reimbursement for them - Fortune
Reasons to Ratain CVS Stock in Your Portfolio Now - Zacks Investment Research
CVS Health stock supported by Baird for future EPS growth once headwinds are addressed - Investing.com
PBM reform looks manageable for CVS Health, says UBS - Yahoo Finance
CVS dispensed opioid drugs unlawfully in profit push, US suit alleges - Yahoo Finance
US Justice Department sues CVS, alleging corporate practices allowed unlawful opioid prescriptions - The Boston Globe
CVS Accused of Illegal Opioid Dispensing in Whistleblower Suit - Insurance Journal
DOJ files complaint against CVS for facilitating unlawful sale of prescription opioids - NBC Philadelphia
CVS hit with civil complaint after DOJ alleges pharmacy filled unlawful prescriptions - Fox Business
CVS Fueled Opioid Epidemic In Rush For Profits, Feds Say - Law360
CVS hit with lawsuit, accused of unlawfully filling opioid prescriptions - AOL
Steps to rein in pharmacy benefit managers in US bill "manageable" for firms - Reuters
CVS Health Corp. stock outperforms competitors on strong trading day - MarketWatch
DOJ accuses CVS of violating Controlled Substances ActProvidence Business First - The Business Journals
CVS accused of illegal opioid dispensing in whistleblower suit - The Boston Globe
US healthcare spending rose 7.5% in 2023, government report says - Marketscreener.com
CVS sued by DOJ for allegedly filling 'unlawful' opioid prescriptions (CVS:NYSE) - Seeking Alpha
Justice Department files nationwide lawsuit accusing CVS of filling ‘unlawful prescriptions’ - WLNE-TV (ABC6)
DOJ sues CVS for unlawfully dispensing controlled substances - Providence Business News
US accuses CVS of filling, billing government for illegal opioid prescriptions - Reuters.com
News | BREAKING: CVS Sued by DOJ for Alleged Violations of Controlled Substances & False Claims Acts - GoLocalProv
Jim Cramer’s Bold Take: Why CVS Health (CVS) Is Struggling in Today’s Healthcare Environment - Insider Monkey
Pharmacy Benefit Managers Played Key Role in Worsening Opioid Crisis, Drug Makers Paid Staggering Rebates To Middlemen: NYT - Benzinga
What to expect from big retailers providing healthcare in 2025 - Modern Healthcare
News | CVS Took Secret Payments for “Free Flow of Opioids,” Says NY Times Investigation - GoLocalProv
CVS Health Corporation (CVS) Announces Early Results and Pricing of Cash Tender Offer - GuruFocus.com
House GOP Asks CVS How Its PBM Treats Smaller Pharmacies - Law360
Feds Intervene In $200M FCA Case Against CVS - Law360
CVS Health Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
What's Going On With CVS Health, UnitedHealth And Cigna Group Shares?CVS Health (NYSE:CVS) - Benzinga
A Closer Look at CVS Health's Options Market Dynamics - Benzinga
Trump ‘Middleman’ Remark Sinks CVS, UnitedHealth, Cigna Shares - MSN
Health Insurers Fall as Pfizer CEO Says Trump Wants PBM Reform - Yahoo Finance
Finanzdaten der Cvs Health Corp-Aktie (CVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):